Edwin M. O'Connor

Mr. O’Connor’s recent initial public offerings and follow-on offerings include:

• argenx NV in its $114 million initial public offering and its $266 million, $300 million and $862 million follow-on offerings
• BeiGene in its $2.7 billion global strategic collaboration with Amgen
• Ascentage Pharma in its $53 million initial public offering on the Hong Kong Stock Exchange
• BeiGene in its $158 million initial public offering and its $200 million, $201 million and $800 million follow-on offerings
• Deciphera Pharmaceuticals in its $127 million initial public offering
• Inotek Pharmaceuticals Corporation in its $40 million initial public offering and a concurrent offering of $20 million offering of convertible senior notes, its $69 million follow-on offering, its $50 million offering of convertible senior notes, and its sale to Rocket Pharmaceuticals
• Moderna in its $604 million initial public offering
• Phreesia in its $167 million initial public offering
• Voyager Therapeutics in its $70 million initial public offering
• The underwriters in Royalty Pharma’s $2.5 billion initial public offering
• The underwriters in Syndax Pharmaceuticals’ $115 million follow-on offering
• The underwriters in Centogene’s $56 million initial public offering
• The underwriters in follow-on offerings for DBV Technologies
• The underwriters in Genfit’s $135 million initial public offering
• The underwriters in PhaseBio Pharmaceuticals’ $46 million initial public offering
• The underwriters in Evelo Biosciences’ $85 million initial public offering
• The underwriters in Arsanis’ $40 million initial public offering 
• The underwriters in Altair Engineering’s $156 million initial public offering, $196 million follow-on offering and $200 million convertible notes offering
• The underwriters in G1 Therapeutics’ $105 million initial public offering, $100 million and $180 million follow-on offerings
• The underwriters in Ovid Therapeutics’ $75 million initial public offering
• The underwriter in BeyondSpring’s $54 million initial public offering
• The underwriters in Reata Pharmaceuticals' $60.5 million initial public offering
• The underwriters in Oncobiologics' $35 million initial public offering
• The underwriters in Trinseo’s $190 million initial public offering*
• The underwriters in Paycom Software’s $100 million initial public offering*

As Vice President in Goldman Sachs’ Investment Banking Division, Mr. O’Connor advised on several initial public offerings, including:

• Cornerstone OnDemand’s $137 million initial public offering
• RPX’s $160 million initial public offering
• Gigamon’s $128.5 million initial public offering
• Jive’s $120 million initial public offering
• Palo Alto Network’s $260 million initial public offering

* Denotes experience prior to joining Goodwin